Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART
| Autor: | Meritxell Lopez, Antoni Campins, Melchor Riera, Francisco Fanjul, Gloria Samperiz, Ángel Ríos, José Luis Valera, Alvar Agusti, María Peñaranda |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pulmonology Cross-sectional study Epidemiology Pulmonary Function Social Sciences HIV Infections Pathology and Laboratory Medicine Immunodeficiency Viruses estudios prospectivos fármacos anti-VIH Smoking Habits Psychology Public and Occupational Health Prospective Studies estudios de cohortes mediana edad education.field_of_study virus diseases adulto Medical Microbiology Viral Pathogens Cohort Medicine Infectious diseases Viral load Cohort study medicine.medical_specialty Science Immunology Therapeutics Microbiology Recreational Drug Use Humans Risk factor education Microbial Pathogens Pharmacology Behavior Organisms Biology and Life Sciences hábito de fumar medicine.disease respiratory tract diseases Cross-Sectional Studies HIV-1 Preventive Medicine estudios transversales Transcription Factors RNA viruses humanos Alcohol abuse estudios de seguimiento Cohort Studies Habits Risk Factors Antiretroviral Therapy Highly Active Medicine and Health Sciences Prospective cohort study Multidisciplinary resultado del tratamiento Smoking factores de transcripción Middle Aged Viral Load Vaccination and Immunization Marijuana DNA-Binding Proteins Treatment Outcome Behavioral Pharmacology Viruses Female carga viral Pathogens VIH-1 Research Article Adult Anti-HIV Agents Population Antiretroviral Therapy Viral diseases Antiviral Therapy Internal medicine Virology Retroviruses VIH (Virus) medicine factores de riesgo Highly-Active Antiretroviral Therapy Cannabis HIV (Viruses) business.industry proteínas de unión al ADN Lentivirus HIV Terapèutica CD4 Lymphocyte Count recuento de linfocitos CD4 Spain Medical Risk Factors infecciones por VIH business Viral Transmission and Infection Follow-Up Studies |
| Zdroj: | PLoS ONE PLoS ONE, Vol 14, Iss 10, p e0224510 (2019) Dipòsit Digital de la UB Universidad de Barcelona |
| ISSN: | 1932-6203 |
| Popis: | Introduction Previous studies have reported that the rate of FEV1 decline over time is increased in HIV patients but the mechanisms underlying this observation are unclear. Since current HIV treatment with Highly Active Antiretroviral Therapy (HAART) results in very good immuneviral control, we hypothesized that HAART should normalize the elevated rate of FEV1 decline previously reported in HIV patients if it was somehow related to the immune alterations caused by HIV, particularly in never smokers or quitters, since smoking is a well established risk factor for accelerated FEV1 decline in the general population. Methods We explored this hypothesis in a prospectively recruited cohort of 188 HIV (smoker and non-smoker) patients treated with HAART in Palma de Mallorca (Spain) and followed-up for 6 years. The cross-sectional characteristics of this cohort have been published elsewhere. Results We found that: (1) HAART resulted in good immune-viral control; (2) the rate of FEV1 decline remained abnormally elevated, even in non-smokers and quitters; and, (3) alcohol abuse during follow-up was related to FEV1 decline in these patients. Discussion Despite adequate immune-viral control by HAART, lung function decline remains increased in most HIV patients, even in non-smokers and quitters. Alcohol abuse is a preventable risk factor to decrease the accelerated FEV1 decline in this population. This work was financed through ABAMI (Balearic Association of Infectious Diseases).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |